Catalog No.
Product Name
Application
Product Information
Citations
-
Aldose Reductase Inhibitor
Floramanoside D is a flavonol glycoside that functions as an aldose reductase inhibitor, with an IC50 value of 2.2 μM, making it effective in the modulation of glucose metabolism. Additionally, it exhibits antioxidant properties by scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH), with an SC50 of 12.5 μM. This compound is valuable for research in diabetes-related complications and oxidative stress studies. -
Aldose Reductase Inhibitor
M 16209 is an orally active inhibitor of aldose reductase (AR), a key enzyme in the polyol pathway. This compound demonstrates effective inhibition of AR from multiple sources, with IC50 values of 0.12 μM for rat lens AR, 0.24 μM for bovine lens AR, 4.5 μM for bovine kidney AR, 1.2 μM for canine lens AR, and 9.3 μM for human placental AR. M 16209 is valuable for research into metabolic diseases, particularly diabetes, by influencing the glucose metabolic pathway and potentially mitigating complications associated with hyperglycemia. -
Aldose Reductase Inhibitor
6-Methoxytricin is an aldose reductase inhibitor derived from Artemisia iwayomogi. This flavonoid demonstrates notable biological activity, with IC50 values of 30.29 μM for aldose reductase inhibition and 134.88 μM for advanced glycation end product formation. Due to its mechanism of action, 6-Methoxytricin is being investigated for its potential to mitigate diabetic complications. -
Aldose Reductase Inhibitor.
ADN 138 is an aldose reductase inhibitor that effectively reduces sorbitol levels in diabetic nerves. This compound leads to significant increases in motor nerve conduction velocity (MNCV) and enhances Na+, K+-ATPase activity in nerve tissues. ADN 138 is valuable for research investigating diabetic neuropathy and related complications, providing insights into potential therapeutic strategies for diabetes-induced nerve damage. -
Aldose Reductase Inhibitor
Hydroxyevodiamine is an aldose reductase inhibitor, demonstrated to have an IC50 value of 24.1 μM. This compound plays a significant role in the regulation of glucose metabolism and is relevant in research related to diabetic complications and oxidative stress. Its inhibitory activity against aldose reductase makes it a valuable tool for studying the biochemical pathways associated with hyperglycemia and related pathologies. -
Aldose Reductase Inhibitor
EBPC is a potent and selective inhibitor of aldose reductase, exhibiting an IC50 of 47 nM. This compound effectively modulates the conversion of glucose to sorbitol, thereby offering significant potential in the study of diabetes-related complications. It serves as a useful tool for researchers investigating the roles of aldose reductase in oxidative stress and diabetic neuropathy. -
Aldose Reductase Inhibitor
(Rac)-Fidarestat is a potent inhibitor of aldose reductase, acting to regulate glucose metabolism and prevent the accumulation of sorbitol in cells. This compound is primarily utilized in research focused on diabetic complications, particularly in relation to neuropathy and retinopathy. Its effectiveness in modulating polyol pathway activity makes it a valuable tool for studying therapeutic approaches to manage hyperglycemia-related tissue damage. -
Aldose Reductase Inhibitor
ARI-809 is a potent and selective aldose reductase inhibitor, exhibiting an IC50 of 1 nM. By inhibiting aldose reductase, ARI-809 effectively reduces excessive glucose flux through the polyol pathway, resulting in the normalization of elevated sorbitol and fructose levels in diabetic models. This compound demonstrates significant potential in alleviating complications associated with diabetes, such as sorbitol accumulation in lens tissues and elevated urinary albumin excretion. ARI-809 is suitable for use in diabetes-related research applications. -
Aldose Reductase Inhibitor
Aldose reductase-IN-6 is a competitive inhibitor of aldose reductase (AR) with an IC50 of 3.164 μM and a Ki value of 0.018 μM. This compound demonstrates effective inhibition without cytotoxic effects on healthy cells, making it a valuable tool for investigating the role of aldose reductase in various biological processes. It is particularly relevant in studies related to diabetic complications and oxidative stress. -
Aldose Reductase Inhibitor
SG-210 is a selective aldose reductase (AR) inhibitor exhibiting potency with IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. By inhibiting aldose reductase, SG-210 effectively reduces sorbitol accumulation, which is beneficial in mitigating complications associated with diabetes, such as neuropathy and retinopathy, in streptozotocin-induced diabetic models. This compound serves as a valuable tool for research into diabetes-related pathologies and the mechanisms underlying metabolic disorders. -
Aldose Reductase 2 Inhibitor
ALR2-IN-10 is an inhibitor of Aldose Reductase 2, exhibiting a modest inhibition rate of 6% at a concentration of 27 μM. This compound is relevant for research related to diabetic complications, providing insights into the pharmacological modulation of glucose metabolism and related pathways. Suitable for studies exploring the therapeutic potential of targeting aldose reductase in diabetes-related tissue damage. -
Aldose Reductase Inhibitor
AD-5467 is a potent and selective inhibitor of aldose reductase, an enzyme involved in glucose metabolism. This compound exhibits significant antidiabetic effects, making it a valuable tool for research in metabolic diseases, particularly diabetes. Its selective inhibition of aldose reductase may aid in understanding the role of this enzyme in diabetic complications and the underlying mechanisms of glucose toxicity. -
Aldose Reductase Inhibitor
Salfredin A3 is an inhibitor of aldose reductase, a key enzyme involved in the polyol pathway. This compound exhibits significant biological activity by reducing the conversion of glucose into sorbitol, thereby mitigating osmotic and oxidative stress in various tissue types. Salfredin A3 is valuable in research applications focusing on diabetic complications and other conditions associated with aldose reductase overactivity. -
Aldose Reductase Inhibitor
Salfredin C2 is an aldose reductase inhibitor that effectively modulates glucose metabolism by inhibiting the conversion of glucose to sorbitol. This compound demonstrates significant biological activity in the treatment of diabetic complications and related conditions. It is particularly useful in research exploring diabetic neuropathy, retinopathy, and nephropathy, highlighting its potential as a therapeutic agent in metabolic disorders. -
Aldose Reductase Inhibitor
Salfredin C1 is an aldose reductase inhibitor that modulates the activity of this enzyme, which plays a crucial role in the polyol pathway. By inhibiting aldose reductase, Salfredin C1 may help mitigate complications associated with hyperglycemia, such as diabetic neuropathy and cataract formation. This reagent is suited for research applications aimed at understanding diabetes-related conditions and developing therapeutic strategies to manage these complications. -
Aldose Reductase Inhibitor
Salfredin C3 is a selective aldose reductase inhibitor that effectively modulates the polyol pathway. By inhibiting aldose reductase, it reduces the conversion of glucose to sorbitol, which plays a critical role in diabetic complications. This compound is valuable in research applications focused on diabetes-related disorders and oxidative stress pathways. -
Aldose Reductase Inhibitor
Salfredin A4 is an aldose reductase inhibitor that selectively modulates the enzyme's activity, impacting glucose metabolism. By inhibiting aldose reductase, it may help reduce sorbitol accumulation, which is relevant in diabetic complications. This compound is primarily utilized in research applications aimed at understanding diabetes-related pathways and the development of neuromodulatory therapies. -
Aldose Reductase Inhibitor
Floramanoside C is a potent aldose reductase inhibitor that demonstrates significant antioxidant activity by scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. This compound is of particular interest in research related to diabetic complications and oxidative stress due to its ability to modulate carbohydrate metabolism. Floramanoside C can be utilized in studies exploring therapeutic options for managing conditions associated with elevated aldose reductase activity. -
Aldose Reductase Inhibitors
4′-Hydroxyflavone is a potent inhibitor of aldose reductase, demonstrating an IC50 value of 12 μM. This compound is significant in the study of diabetic complications and oxidative stress, as it can modulate glucose metabolism pathways. Its inhibition of aldose reductase makes it valuable for research applications focused on metabolic diseases and related therapeutic developments. -
Aldose Reductase Inhibitor
WF-3681 is a selective aldose reductase inhibitor, derived from fungal metabolites. This compound effectively inhibits the enzyme aldose reductase, which plays a crucial role in the polyol pathway, leading to the conversion of glucose to sorbitol. WF-3681 has strong potential in research applications related to diabetes complications and associated metabolic disorders, where oxidative stress and sorbitol accumulation are involved. -
Aldose Reductase Inhibitor
Salfredin B11 is an aldose reductase inhibitor that effectively modulates glucose metabolism by reducing the conversion of glucose to sorbitol. This compound exhibits significant biological activity in the context of diabetic complications, particularly in preventing neuropathy and retinopathy. Salfredin B11 is a valuable tool for research applications focused on the treatment of diabetes-related disorders and the study of oxidative stress responses. -
Aldose Reductase Inhibitor
2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole is an aldose reductase (ALR2) inhibitor, demonstrating significant biological activity in modulating glucose metabolism and potentially mitigating diabetic complications. This compound has also shown efficacy in inhibiting larval settlement in marine invertebrates, including barnacles, bryozoans, and polychaetes, while maintaining low toxicity. Its unique properties make it a valuable reagent for research in both diabetes and ecological studies. -
Aldose Reductase Inhibitor
Alrestatin sodium is an aldose reductase inhibitor that plays a significant role in modulating hyperglycemic conditions associated with diabetes mellitus. By inhibiting this enzyme, Alrestatin sodium helps to alleviate oxidative stress and cellular damage, contributing to the prevention of diabetic complications such as neuropathy. This compound is primarily utilized in research focused on diabetes-related pathologies and the development of therapeutic strategies. -
Aldose Reductase Inhibitor
MK181 is an aldose reductase (AR) inhibitor, demonstrating IC50 values of 0.71 μM for aldose reductase and 4.5 μM for AKR1B10. This compound engages the external loop A subpocket of AKR1B10, providing a targeted approach to modulating enzyme activity. MK181 is primarily utilized in research exploring diabetic complications and oxidative stress pathways, making it a valuable tool in pharmacological studies related to metabolic disorders. -
Aldose Reductase Inhibitor
MK 319 is a selective inhibitor of aldose reductase (AR) with an IC50 value of 0.3 μM. This compound is of particular interest in diabetes research, where it may be used to investigate pathways associated with diabetic complications. Additionally, MK 319's role in modulating glucose metabolism can provide insights into therapeutic strategies for managing diabetes and its related disorders. -
Aldose Reductase Inhibitor
Carboxy finasteride is a significant metabolite of the 5α-reductase inhibitor finasteride, targeting aldose reductase. As a biotransformation product of finasteride, it is primarily formed through oxidation by cytochrome P450 (CYP3A4) and represents the predominant metabolite found in urine, while hydroxy finasteride is more prevalent in plasma. This compound plays a crucial role in research related to metabolic pathways and the pharmacokinetics of finasteride, contributing to studies on diabetic complications and related enzymatic activities. -
Aldose Reductase Inhibitor
M79175 is an aldose reductase inhibitor that plays a crucial role in the management of diabetic complications. By inhibiting the enzyme, M79175 assists in the reduction of sorbitol accumulation, which is implicated in the pathogenesis of diabetic retinopathy. This reagent is relevant for researchers investigating early stages of diabetic retinopathy and potential therapeutic strategies for diabetes-related ocular disorders. -
Aldose Reductase Inhibitor
AL-4114 is a potent aldose reductase inhibitor that plays a critical role in the management of diabetic complications. This compound has demonstrated significant biological activity in the prevention of diabetic cataractogenesis, making it valuable for research focused on diabetes-related ocular disorders. Its application extends to the investigation of metabolic pathways and the development of therapeutic strategies for diabetes management. -
Aldose Reductase Inhibitor
ALO1567 is an orally available aldose reductase inhibitor that demonstrates an IC50 of 27 nM against rat lens aldose reductase. This compound is utilized in research focused on diabetes, particularly in studying the pathways related to hyperglycemia and osmotic stress in diabetic complications. Its specific targeting of aldose reductase makes it a valuable tool for investigating therapeutic strategies in metabolic disorders. -
Aldose Reductase Inhibitor
Salfredin A7 is an aldose reductase inhibitor that targets the enzyme responsible for converting glucose into sorbitol. This activity is significant in the context of diabetic complications, where the accumulation of sorbitol leads to cellular damage. Salfredin A7 exhibits anti-inflammatory properties and has potential applications in research focusing on diabetes-related pathologies and oxidative stress. Its inhibitory action on aldose reductase makes it a valuable reagent for studies investigating metabolic diseases and their associated complications. -
Aminopeptidase N/Leukotriene A4 Hydrolase Inhibitor
Bestatin trifluoroacetate is a potent inhibitor of CD13 (Aminopeptidase N) and leukotriene A4 hydrolase. It plays a significant role in cancer research by modulating enzymatic activity associated with tumor progression and inflammation. With its capability to interfere with amino acid metabolism, Bestatin trifluoroacetate is valuable for studying the biological processes linked to these targets. -
Aminopeptidase N/Leukotriene A4 Hydrolase Inhibitor
Bestatin hydrochloride is an inhibitor of aminopeptidase N (CD13) and leukotriene A4 hydrolase. It plays a significant role in cancer research by modulating the enzymatic activities associated with tumor progression and inflammatory processes. This compound is valuable for studies investigating the implications of aminopeptidases in tumor microenvironments and immune responses. -
DHODH Inhibitor
DSM502 is a pyrrole-based inhibitor targeting Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and effectively inhibits Plasmodium parasites while showing no activity against mammalian DHODHs. This selectivity makes DSM502 a valuable tool for research into malaria and other Plasmodium-related diseases. -
Proteasome Inhibitor
LXE408 is an orally active, non-competitive inhibitor of the proteasome, exhibiting selective action against kinetoplastids. With an IC50 of 0.04 μM for the L. donovani proteasome, LXE408 effectively inhibits parasite proliferation, demonstrated by an EC50 of 0.04 μM against L. donovani. Due to its limited ability to cross the blood-brain barrier, LXE408 is particularly suitable for research focused on visceral leishmaniasis (VL). -
Kinetoplastid Proteasome Inhibitor
GNF6702 is a selective inhibitor of the kinetoplastid proteasome, targeting the degradation pathway critical for parasite survival. This compound demonstrates potent activity against various kinetoplastid parasites and has shown efficacy in clearing infections in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis. GNF6702 is valuable for research focused on developing therapies for these neglected tropical diseases. -
DHODH Inhibitor
DSM705 hydrochloride is a potent inhibitor of Dihydroorotate Dehydrogenase (DHODH), targeting the enzymatic activity essential for the de novo pyrimidine synthesis in Plasmodium species. It demonstrates high nanomolar potency against P. falciparum and P. vivax DHODH with IC50 values of 95 nM and 52 nM, respectively, while sparing mammalian DHODH enzymes. This compound is valuable for research into antimalarial therapeutics and understanding the biochemical mechanisms of Plasmodium infections. -
L. donovani Proteasome Inhibitor
GSK3494245 is a selective inhibitor of the chymotrypsin-like activity of the Leishmania donovani proteasome, targeting a site between the β4 and β5 subunits with an IC50 of 0.16 μM. This compound demonstrates moderate inhibitory effects on the chymotrypsin-like activity of human proteasomes, exhibiting IC50 values of 13 µM in purified 26S and 40 µM in enriched THP-1 extracts. GSK3494245's potent activity and favorable biosafety profile make it a valuable tool for research in parasitology and potential therapeutic applications against leishmaniasis. -
Tyrosinase Inhibitor
Polyphyllin C is a spirostanol saponin that acts as a tyrosinase inhibitor. It demonstrates mild inhibitory activity against tyrosinase with an IC50 of 36.87 µM. Additionally, Polyphyllin C exhibits moderate antileishmanial effects, with an IC50 of 1.59 µg/mL, making it a candidate for research in skin pigmentation disorders and leishmaniasis treatment. -
PfDHODH Inhibitor
PfDHODH-IN-2 is a specific inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH), exhibiting potent activity with an IC50 of 1.11 µM. This compound serves as an effective antimalarial agent, making it valuable for research focused on malaria and the development of therapeutic strategies against this disease. Its mechanism of action targets the pyrimidine biosynthesis pathway, providing a crucial approach for disrupting parasite proliferation. -
DHODH Inhibitor
DSM705 is a pyrrole-based inhibitor of Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and exhibits significant activity against Plasmodium parasites while sparing mammalian DHODHs. This compound is a potent antimalarial agent, making it a valuable tool for research in malaria treatment and related studies. -
HCV Protease Inhibitor
MK-2748 is a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It demonstrates broad-spectrum antiviral activity across all genotypes (gt1a-gt6) with nanomolar potency (IC₅₀ < 0.115 nM), including strong efficacy against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 is valuable for research on HCV infection and contributes to the understanding of antiviral mechanisms and treatment strategies. -
HCV Protease Inhibitor
AL-611 is an inhibitor of the Hepatitis C virus (HCV) NS5B polymerase, demonstrating potent activity with an EC50 value of 5 nM. This compound plays a critical role in antiviral research, particularly in the development of therapeutic strategies against HCV infections. Its effectiveness in inhibiting HCV replication makes it a valuable tool for studies focused on viral RNA synthesis and enzyme interactions. -
HCV Protease Inhibitor
GSK2818713 is a selective Hepatitis C virus (HCV) protease inhibitor that disrupts the replication complex associated with the NS5A protein. This compound exhibits potent anti-HCV activity, making it a valuable tool for studying the replication and life cycle of the virus. GSK2818713 is applicable in research focused on developing therapeutic strategies against Hepatitis C. -
HCV Protease Inhibitor
BI-1230 is a potent inhibitor of the HCV NS3 protease, exhibiting nanomolar activity in blocking viral replication. It demonstrates high selectivity against other serine and cysteine proteases, making it a valuable tool for studying hepatitis C virus infection mechanisms. Additionally, BI-1230 shows favorable pharmacokinetic properties, supporting its potential use in drug development and research applications related to antiviral therapy. -
HCV Protease Inhibitor
MK-6169 is a potent hepatitis C virus (HCV) protease inhibitor that targets the viral NS5A protein. It exhibits broad-spectrum activity against various HCV genotypes, making it a valuable tool for research on antiviral therapies in hepatitis C. This compound is useful for exploring the mechanisms of HCV replication and potential treatment strategies in pharmaceutical development. -
HCV Protease Inhibitor
Isoeuphorbetin is a dimeric coumarin that acts as a potent inhibitor of HCV protease, demonstrated by an IC50 value of 3.63 µg/mL. This compound has significant potential in antiviral research, particularly in the development of therapeutics targeting hepatitis C virus infection. Its ability to effectively block viral protease activity makes it a valuable tool for studying HCV biology and drug discovery. -
HCV Protease Inhibitor
Ac-D-DGla-LI-Cha-C is a potent inhibitor of the hepatitis C virus (HCV) protease, effectively disrupting viral replication. This peptide is instrumental in studying various biological processes and diseases, including cancer, autoimmune disorders, fibrotic conditions, inflammatory responses, neurodegenerative diseases, infectious diseases, lung and cardiovascular disorders, as well as metabolic diseases. Its targeted action on HCV protease makes it a valuable tool for research in virology and therapeutic development. -
Calpain Inhibitor
Calpain Inhibitor V (Mu-Val-HPh-FMK) is an irreversible inhibitor of calpain, designed for effective cellular penetration. This compound exhibits notable anti-chlamydial activity and is utilized in research exploring calpain-mediated pathways and their implications in various diseases. Its application extends to studies focused on cellular signaling processes and the therapeutic potential of calpain modulation. -
Dopamine receptor Agonist, 20S proteasome Activator
Apomorphine hydrochloride is a potent dopamine receptor agonist and a known activator of the 20S proteasome. It enhances proteasomal and insulin-degrading enzyme activities, facilitating the degradation of intracellular amyloid-beta (Aβ), phosphorylated tau (p-tau), and p53, thereby reducing their levels in neuronal cells. This compound is particularly relevant for research focused on neurodegenerative disorders such as Alzheimer's disease and psychiatric conditions including schizophrenia. -
AT1/NEP Inhibitor
TD-0212 TFA is an orally active dual pharmacology inhibitor targeting the angiotensin II type 1 receptor (AT1) and neprilysin (NEP). With a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP, this compound exhibits significant biological activity in modulating cardiovascular and neuroprotective pathways. TD-0212 TFA is suitable for research applications exploring the roles of AT1 antagonism and neprilysin inhibition in various disease models.
